Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

and VA111913 for dysmenorrhoea, product candidates which directly target the causes of conditions that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia was spun out from Ferring Research Ltd in 2008 and its pipeline is driven by the proven small molecule drug discovery and development capabilities of that unit and Vantia's experienced management team. Vantia's strategy is to develop candidates to Phase II proof-of-concept and then commercialise through partnerships. The Company is well-funded and backed by specialist life science investors MVM Life Science Partners, SV Life Sciences and Novo A/S.

http://www.vantiatherapeutics.com.

About VA106483 and nocturia:

VA106483 is a novel small molecule drug candidate in Phase II trials to treat nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate, thus interrupting sleep. VA106483 acts directly in the collecting ducts of the kidney by binding to vasopressin 2 receptors, decreasing urine volume. Clinical data indicate that VA106483 is generally well tolerated and an effective anti-diuretic that increases urine concentration and reduces urine output.

Vantia's initial indication for VA106483 is nocturia. A Phase II clinical programme has been designed and trials are underway, with initial results expected mid 2009.

Nocturia is commonly associated with benign prostatic hypertrophy (BPH) where it is estimated to affect up to 70% of BPH patients. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need and estimated to be worth in excess of US$500m per annum. This market opportunity presents only part of
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech ... R&D capability and technology platform company serving the pharmaceutical, ... Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), ... Kong with 20 years of operations in ... two companies have signed an agreement whereby WuXi,s Laboratory ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... the course of any week, in my role as co-founder ... of CCC, I meet many interesting entrepreneurs, IT professionals, business ... events from which I desire to share my observations. I ... have some fun revisiting my experiences. My first Journal is ...
... technology are outstripping the development of new drugs ... preventing disease. Today, information networks are making it ... and advances in genetic profiling are enabling doctors ... A flagship one-day symposium, "From Fail and Fix ...
... Helping Protect Against Wireless Hacking and Rogue Access ... of the information technology industry's first comprehensive intrusion ... security breaches on wireless local area networks. ... managed security service that melds IBM Global Services' ...
Cached Biology Technology:Mr. Jackson Goes to Washington 2Mr. Jackson Goes to Washington 3Mr. Jackson Goes to Washington 4Symposium To Explore Information Technology's Impact on Improving Quality, Cost Effectiveness of Healthcare 2IBM Develops Wireless Security Service 2
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Simplifying the process for forming compounds that can ... and plastics, has earned one University of Houston chemist ... professor of chemistry in the College of Natural Sciences ... scientists, mathematicians and economists in the United States and ...
... has discovered clumps of previously-unreported callus hairs growing in ... varieties, which may have storage implications for commercial growers. ... really exciting, says Dr Mary Parker of the Institute ... as long as human history and Fuji apples are ...
... cropping systems be as productive as conventional systems" The ... and a qualified Yes most of the time for ... at the University of Wisconsin-Madison and agricultural consulting firm ... The researchers primarily based their answer on results from ...
Cached Biology News:Simplifying manufacture of drugs, plastics earns UH chemist top honor 2Popular apple variety harbors unusual cell growth 2Are organic crops as productive as conventional? 2